ncRNA basic information ncRNA ID: MI0000449 ncRNA Database: miRBase ncRNA Name: miR-132 ncRNA Type: miRNA ncRNA Expression: up-regulated ncRNA Method: qRT-PCR ncRNA Target Gene: PTEN ncRNA Pathway: PTEN-AKT/NF-kappaB signaling pathway Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00997 (APRD00185, DB05331, DB05847) Drug Name: Doxorubicin Drug Method: Quantitative real-time PCR (qRT-PCR) was used to quantify the expression of miR-132/-212 (miR-132 and miR-212) in doxorubicin (DOX)-resistant and -sensitive breast cancer tumors and cells. The function of miR-132/-212 in drug resistance was investigated in vitro (MTT assay, TUNEL assay, fluorescence, immunohistochemistry, luciferase reporter assay, Western blotting). We found that miR-132/-212 were commonly overexpressed in DOX-resistant breast cancer tumors and cells. Silenced miR-132/-212 expression induced DOX accumulation in MCF-7/ADR cells, while overexpression of miR-132/-212 led to breast cancer resistance protein (BCRP)-based DOX efflux in MCF-7 cells. Further study showed that up-regulation of miR-132/-212 in MCF-7/ADR cells suppressed the expression of PTEN, a target gene of miR-132/-212, which activated AKT phosphorylation and the NF-kB pathway and led to increased BCRP expression. Down-regulation of miR-132/-212 sensitized MCF-7/ADR cells to DOX. Mechanistic investigations suggested that miR-132/-212 enhancement was a result of NF-kappaB-mediated transactivation of the pri-miR-132/-212 gene. Drug Response: resistant

Cancer basic information Cancer: breast cancer Tissue/Cell: cell line (MCF-7,MCF-7/ADR)

Other information Title: MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-kappaB signaling pathway in breast cancer. Journal: Biomed Pharmacother Published: 2018 PubMed ID: 29567542